Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: Aids to smoking cessation

Journal of Medicinal Chemistry

Volumn 53, Issue 12, 2010, Pages 4731-4748

  Lukas, Ronald J ^a   Muresan, Ana Z ^b   Damaj, M Imad ^c   Blough, Bruce E ^b   Huang, Xiaodong ^b   Navarro, Hernán A ^b   Mascarella, S Wayne ^b   Eaton, J Brek ^a   Marxer Miller, Syndia K ^a   Carroll, F Ivy ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b RTI INTERNATIONAL   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 BROMOPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3 CHLOROPHENYL) 3 ETHYL 5,5 DIMETHYLMORPHOLIN 2 OL; 2 (3 CHLOROPHENYL) 3,4,5,5 TETRAMETHYLMORPHOLIN 2 OL; 2 (3 CHLOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3 CHLOROPHENYL) 5,5 DIMETHYL 3 PROPYLMORPHOLIN 2 OL; 2 (3 FLUOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3 METHOXYPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3 NITROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3,4 DICHLOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3,4 DIFLUOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3,5 DICHLOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (3,5 DIFLUOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (4 CHLOROPHENYL) 3,4,5,5 TETRAMETHYLMORPHOLIN 2 OL; 2 (4 CHLOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (4 FLUOROPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (4 METHOXYPHENYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (M TOLYL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (NAPHTHALEN 1 YL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 (NAPHTHALEN 2 YL) 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 BIPHENYL 4 YL 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 2 PHENYL 3,5,5 TRIMETHYLMORPHOLIN 2 OL; 3,5,5 TRIMETHYL 2 (4 METHYLPHENYL)MORPHOLIN 2 OL; 3,5,5 TRIMETHYL 2 (PYRIDIN 2 YL)MORPHOLIN 2 OL; 3,5,5 TRIMETHYL 2 (PYRIDIN 3 YL)MORPHOLIN 2 OL; ANALGESIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PAIN; SMOKING CESSATION;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS; ANIMALS; BODY TEMPERATURE; BUPROPION; CELL LINE; DOPAMINE UPTAKE INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; SEROTONIN UPTAKE INHIBITORS; SMOKING CESSATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953756282     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1003232     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Smoking and Tobacco Use-Fact Sheet: Health Effects of Cigarette Smoking, (updated January 2008), http://www.cdc.gov/tobacco/data-statistics/fact-sheets/health-effects/ effects-cig-smoking/.
2. US Department of Health and Human Services. The Health Consequences of Smoking: What It Means to You; NIH: Atlanta, GA, 2004.
3. SAMHSA (Substance Abuse and Mental Health Services Administration). Results from the 2008 National Survey on Drug Use and Health; Department of Health and Human Services: Washington, DC, 2009.
4. Lerman, C.; LeSage, M. G.; Perkins, K. A.; OMalley, S. S.; Siegel, S. J.; Benowitz, N. L.; Corrigall, W. A. Translational research in medication development for nicotine dependence Nat. Rev. Drug Discovery 2007, 6, 746-762
5. Le Novere, N.; Corringer, P. J.; Changeux, J. P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences J. Neurobiol. 2002, 53, 447-456
6. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi, F.; Zoli, M. Heterogeneity and complexity of native brain nicotinic receptors Biochem. Pharmacol. 2007, 74, 1102-1111
7. Marks, M. J.; Collins, A. C. Characterization of nicotine binding in mouse brain and comparison with the binding of α-bungarotoxin and quinuclidinyl benzilate Mol. Pharmacol. 1982, 22, 554-564
8. Rahman, S.; Lopez-Hernandez, G. Y.; Corrigall, W. A.; Papke, R. L. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction CNS Neurol. Disord. Drug Targets 2008, 7, 422-441
9. Adams, D. J.; Nutter, T. J. Calcium permeability and modulation of nicotinic acetylcholine receptor-channels in rat parasympathetic neurons J. Physiol. (Paris) 1992, 86, 67-76
10. Le Novere, N.; Zoli, M.; Changeux, J. P. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain Eur. J. Neurosci. 1996, 8, 2428-2439
11. Goldner, F. M.; Dineley, K. T.; Patrick, J. W. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area Neuroreport 1997, 8, 2739-2742
12. Exley, R.; Clements, M. A.; Hartung, H.; McIntosh, J. M.; Cragg, S. J. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens Neuropsychopharmacology 2008, 33, 2158-2166
13. Taly, A.; Corringer, P. J.; Guedin, D.; Lestage, P.; Changeux, J. P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discovery 2009, 8, 733-750
14. Corrigall, W. A.; Franklin, K. B.; Coen, K. M.; Clarke, P. B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine Psychopharmacology 1992, 107, 285-289
15. Brody, A. L.; Olmstead, R. E.; London, E. D.; Farahi, J.; Meyer, J. H.; Grossman, P.; Lee, G. S.; Huang, J.; Hahn, E. L.; Mandelkern, M. A. Smoking-induced ventral striatum dopamine release Am. J. Psychiatry 2004, 161, 1211-1218
16. Johnston, A. J.; Ascher, J.; Leadbetter, R.; Schmith, V. D.; Patel, D. K.; Durcan, M.; Bentley, B. Pharmacokinetic optimization of sustained-release bupropion for smoking cessation Drugs 2002, 62 (Suppl 2) 11-24 (Pubitemid 34809711)
17. Hesse, L. M.; Venkatakrishnan, K.; Court, M. H.; von Moltke, L. L.; Duan, S. X.; Shader, R. I.; Greenblatt, D. J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants Drug Metab. Dispos. 2000, 28, 1176-1183
18. Faucette, S. R.; Hawke, R. L.; Lecluyse, E. L.; Shord, S. S.; Yan, B.; Laethem, R. M.; Lindley, C. M. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity Drug Metab. Dispos. 2000, 28, 1222-1230
19. Faucette, S. R.; Hawke, R. L.; Shord, S. S.; Lecluyse, E. L.; Lindley, C. M. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation Drug Metab. Dispos. 2001, 29, 1123-1129
20. Bondarev, M. L.; Bondareva, T. S.; Young, R.; Glennon, R. A. Behavioral and biochemical investigations of bupropion metabolites Eur. J. Pharmacol. 2003, 474, 85-93
21. Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors Mol. Pharmacol. 2004, 66, 675-682
22. Jefferson, J. W.; Pradko, J. F.; Muir, K. T. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations Clin. Ther. 2005, 27, 1685-1695
23. Kharasch, E. D.; Mitchell, D.; Coles, R. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity J. Clin. Pharmacol. 2008, 48, 464-474
24. Fang, Q. K.; Han, Z.; Grover, P.; Kessler, D.; Senanayake, C. H.; Wald, S. A. Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an α-ketotriflate Tetrahedron: Asymmetry 2000, 11, 3659-3663
25. Kelley, J. L.; Musso, D. L.; Boswell, G. E.; Soroko, F. E.; Cooper, B. R. (2 S,3 S,5 R)-2-(3,5-Difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake J. Med. Chem. 1996, 39, 347-349
26. Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type J. Pharmacol. Exp. Ther. 1999, 289, 877-885
27. Damaj, M. I.; Fei-Yin, M.; Dukat, M.; Glassco, W.; Glennon, R. A.; Martin, B. R. Antinociceptive responses to nicotinic acertylcholine receptors ligands after systemic amd inthathecal administration in mice J. Pharmacol. Exp. Ther. 1998, 284, 1058-1065
28. Carroll, F. I.; Blough, B. E.; Mascarella, S. W.; Navarro, H. A.; Eaton, J. B.; Lukas, R. J.; Damaj, M. I. Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking Cessation J. Med. Chem. 2010, 53, 2204-2214
29. Silverstone, P. H.; Williams, R.; McMahon, L.; Fleming, R.; Fogarty, S. Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice Ann. Gen. Psychiatry 2008, 7, 27
30. Carroll, F. I.; Blough, B.; Abraham, P.; Mills, A. C.; Holleman, J. A.; Wolckenhauer, S. A.; Decker, A. M.; Landavazo, A.; McElroy, K. T.; Navarro, H. A.; Gatch, M. B.; Foster, M. J. Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Cocaine Addiction J. Med. Chem. 2009, 52, 6768-6781
31. Anderson, W. K.; Jones, A. N. Synthesis and evaluation of furan, thiophene, and azole bis[(carbamoyloxy)methyl] derivatives as potential antineoplastic agents J. Med. Chem. 1984, 27, 1559-1565
32. Hoffman, R. V.; Tao, J. A simple, stereoselective synthesis of ketomethylene dipeptide isosteres Tetrahedron 1997, 53, 7119-7125
33. Koch, T. H.; Olesen, J. A.; DeNiro, J. Unusually weak carbon-carbon single bond J. Am. Chem. Soc. 1975, 97, 7285-7288
34. Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; Gentry, C. L. Some methods for studies of nicotinic acetylcholine receptor pharmacology. In Nicotinic Receptors and the Nervous System; Levin, E. D., Ed.; CRC Press: Boca Raton, 2002; pp 3 - 27.
35. Eaton, J. B.; Peng, J. H.; Schroeder, K. M.; George, A. A.; Fryer, J. D.; Krishnan, C.; Buhlman, L.; Kuo, Y. P.; Steinlein, O.; Lukas, R. J. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells Mol. Pharmacol. 2003, 64, 1283-1294
36. Gentry, C. L.; Lukas, R. J. Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes J. Pharmacol. Exp. Ther. 2001, 299, 1038-1048
37. Marubio, L. M.; del Mar Arroyo-Jimenez, M.; Cordero-Erausquin, M.; Lena, C.; Le Novere, N.; de Kerchove dExaerde, A.; Huchet, M.; Damaj, M. I.; Changeux, J. P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits Nature 1999, 398, 805-810
38. DAmour, F. E.; Smith, D. L. A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 1941, 72, 74-79